Cargando…

Trends in Transcatheter Aortic Valve Implantation in Australia

Aortic valve stenosis is the most common valvular lesion in Australia, with a rising prevalence in line with the ageing population. Recent trials have demonstrated the efficacy of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement in consecutively lower surgical...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Rhys, Sarathy, Kiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977994/
https://www.ncbi.nlm.nih.gov/pubmed/35401791
http://dx.doi.org/10.15420/icr.2021.27
_version_ 1784680885540356096
author Gray, Rhys
Sarathy, Kiran
author_facet Gray, Rhys
Sarathy, Kiran
author_sort Gray, Rhys
collection PubMed
description Aortic valve stenosis is the most common valvular lesion in Australia, with a rising prevalence in line with the ageing population. Recent trials have demonstrated the efficacy of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement in consecutively lower surgical risk patient cohorts. Despite this, the current indication for TAVI in Australia is for the treatment of severe symptomatic aortic stenosis in patients who are of prohibitive or high surgical risk and ultimately deemed suitable by a heart team. This article summarises the trends in TAVI in Australia over the last 5 years in terms of funding, accreditation and service delivery, as well as advances in technique, technology, patient selection and local outcomes.
format Online
Article
Text
id pubmed-8977994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-89779942022-04-07 Trends in Transcatheter Aortic Valve Implantation in Australia Gray, Rhys Sarathy, Kiran Interv Cardiol Structural Aortic valve stenosis is the most common valvular lesion in Australia, with a rising prevalence in line with the ageing population. Recent trials have demonstrated the efficacy of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement in consecutively lower surgical risk patient cohorts. Despite this, the current indication for TAVI in Australia is for the treatment of severe symptomatic aortic stenosis in patients who are of prohibitive or high surgical risk and ultimately deemed suitable by a heart team. This article summarises the trends in TAVI in Australia over the last 5 years in terms of funding, accreditation and service delivery, as well as advances in technique, technology, patient selection and local outcomes. Radcliffe Cardiology 2022-03-21 /pmc/articles/PMC8977994/ /pubmed/35401791 http://dx.doi.org/10.15420/icr.2021.27 Text en Copyright © 2022, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Structural
Gray, Rhys
Sarathy, Kiran
Trends in Transcatheter Aortic Valve Implantation in Australia
title Trends in Transcatheter Aortic Valve Implantation in Australia
title_full Trends in Transcatheter Aortic Valve Implantation in Australia
title_fullStr Trends in Transcatheter Aortic Valve Implantation in Australia
title_full_unstemmed Trends in Transcatheter Aortic Valve Implantation in Australia
title_short Trends in Transcatheter Aortic Valve Implantation in Australia
title_sort trends in transcatheter aortic valve implantation in australia
topic Structural
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977994/
https://www.ncbi.nlm.nih.gov/pubmed/35401791
http://dx.doi.org/10.15420/icr.2021.27
work_keys_str_mv AT grayrhys trendsintranscatheteraorticvalveimplantationinaustralia
AT sarathykiran trendsintranscatheteraorticvalveimplantationinaustralia